Pioneering Potentially Life-Changing Conditionally Activated Therapeutics
Advancing our pipeline
Our expanding pipeline of Probody® therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics through our own bold science and partnerships with some of the world’s leading biopharmaceutical companies.
Research & development
Wholly-Owned or US Rights*
CX-2009 The company is currently enrolling patients in the PROCLAIM-CX-2009 study. More
*U.S. Rights include wholly-owned molecules or collaboration molecules in which CytomX has a right or option to share in U.S. commercial profits
Collaborator Directed Pipeline
Lead candidates
We are utilizing our Probody® platform to develop potential best-in-class therapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult-to-treat targets.
We believe our Probody therapeutics have the potential to:
- Create or widen therapeutic window – the balance between a therapy’s dose that is effective without causing unacceptable toxicity
- Enable new combinations of drugs previously not possible due to toxicities
- Expand the universe of viable therapeutic targets by opening “undruggable” target space
- Make new treatment options possible for more patients
CX-2029
(CD71-directed conditionally activated antibody-drug conjugate)
CytomX and AbbVie are co-developing CX-2029, a conditionally activated antibody-drug conjugate (ADC) directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy.
CD71 is an excellent “internalizer,” with the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX published initial Phase 1 data in the peer-reviewed journal Clinical Cancer Research validating CD71 as a first-in-class oncology target with encouraging clinical activity observed. CX-2029 is in a Phase1/2 clinical trial studying four dose-expansion cohorts: head and neck cancer, squamous non-small cell lung cancer, and esophageal carcinoma.
CX-904
(EGFRc-CD3 conditionally activated T cell engaging bispecific)
CytomX and Amgen are developing CX-904, a T-cell-engaging bispecific Probody candidate against the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells. The drug candidate is currently in a Phase 1 dose-escalation study in patients with advanced solid tumors.
CX-2051
(EpCAM-directed conditionally activated antibody-drug conjugate)
CX-2051 is a wholly-owned conditionally activated ADC directed toward the epithelial cell adhesion molecule (EpCAM), with potential applicability across multiple EpCAM-expressing epithelial cancers. EpCAM is a validated anti-cancer target for which systemic therapies not yet been developed due to widespread expression on normal tissues. CX-2051 is designed to open a therapeutic window for a systemically administered anti-EpCAM ADC.
CX-801
(Interferon alpha-2b Probody cytokine)
CX-801 is a wholly-owned interferon (IFN) alpha-2b Probody. Interferons are approved anti-cancer therapies but are limited by narrow therapeutic windows. Based on preclinical studies, CX-801 demonstrated a wide therapeutic index with an enhanced tolerability profile versus unmasked IFN, without compromising its potent antitumor effects. CX-801 has broad potential applicability in traditionally immuno-oncology sensitive as well as
insensitive (cold) tumors
BMS-986288
(CTLA-4-targeted conditionally activated therapeutic)
Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of an anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-targeted Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers.
Clinical trials
Several of our most promising drug candidates are currently in clinical trials, investigating their potential utility in a number of advanced or recurrent cancers.
Learn More